ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 205,194 | 88,334 | 60,241 | 137,658 |
| Marketable securities | 175,685 | 154,484 | 197,572 | 16,000 |
| Accounts receivable, net | 43,271 | 42,571 | 32,016 | 22,126 |
| Inventories | 547 | 910 | 6,703 | 6,640 |
| Due from related parties-Related Party | 3 | 46 | 18 | 204 |
| Prepaid expenses and other current assets-Nonrelated Party | 26,182 | 27,761 | 31,451 | 23,270 |
| Prepaid expenses and other current assets-Related Party | 2,071 | 769 | 1,496 | 2,234 |
| Total current assets | 452,953 | 314,875 | 329,497 | 208,132 |
| Property, plant and equipment, net | 112,785 | 114,264 | 129,597 | 133,004 |
| Non-marketable equity investment | 12,885 | 13,953 | 14,475 | 14,977 |
| Long-term inventories | 18,856 | 13,508 | NaN | NaN |
| Convertible note receivable | 0 | 7,380 | 7,317 | 7,254 |
| Operating lease right-of-use assets, net-Nonrelated Party | 20,573 | 19,808 | 19,273 | 20,103 |
| Operating lease right-of-use assets, net-Related Party | 12,461 | 13,202 | 13,922 | 14,620 |
| Other assets-Nonrelated Party | 15,746 | 4,530 | 4,473 | 3,553 |
| Other assets-Related Party | 378 | 378 | 433 | 433 |
| Total assets | 646,637 | 501,898 | 518,987 | 402,076 |
| Accounts payable-Nonrelated Party | 11,192 | 6,978 | 5,773 | 7,419 |
| Accrued expenses and other liabilities | 48,204 | 46,838 | 43,602 | 35,705 |
| Operating lease liabilities-Nonrelated Party | 4,690 | 4,291 | 3,770 | 3,682 |
| Operating lease liabilities-Related Party | 2,936 | 3,244 | 3,546 | 3,710 |
| Accounts payable-Related Party | 930 | 403 | 443 | 128 |
| Total current liabilities | 67,952 | 61,754 | 57,134 | 50,644 |
| Related-party convertible note payable, at fair value-Related Party | 678,386 | 477,093 | 500,804 | 492,084 |
| Revenue interest liability | 404,299 | 324,615 | 316,145 | 307,049 |
| Operating lease liabilities, less current portion-Nonrelated Party | 20,062 | 19,732 | 19,805 | 20,798 |
| Operating lease liabilities, less current portion-Related Party | 13,085 | 13,715 | 14,325 | 15,042 |
| Derivative liabilities | 23,314 | 19,722 | 18,322 | 18,611 |
| Warrant liabilities | 308,193 | 84,417 | 115,160 | 66,957 |
| Other liabilities | 472 | 424 | 702 | 710 |
| Total liabilities | 1,515,763 | 1,001,472 | 1,042,397 | 971,895 |
| Common stock, 0.0001 par value 1,650,000,000 shares authorized as of march31,2026 and december31, 2025 1,047,341,146 and 1,011,800,008 shares issued and outstanding as of march31,2026 and december31, 2025, respectively excluding treasury stock, 163,800shares outstanding as of march31,2026 and december31, 2025 | 104 | 101 | 98 | 91 |
| Additional paid-in capital | 3,461,865 | 3,197,120 | 3,135,288 | 3,014,041 |
| Accumulated deficit | -4,359,428 | -3,726,646 | -3,664,702 | -3,597,449 |
| Accumulated other comprehensive income | 27,453 | 28,956 | 4,997 | 12,568 |
| Total immunitybio stockholders deficit | -870,006 | -500,469 | -524,319 | -570,749 |
| Noncontrolling interests | 880 | 895 | 909 | 930 |
| Total stockholders deficit | -869,126 | -499,574 | -523,410 | -569,819 |
| Total liabilities and stockholders deficit | 646,637 | 501,898 | 518,987 | 402,076 |